Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...

Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...

Dear Fellow Shareholders of Inhibikase Therapeutics: 2024 has been off to a productive start for Inhibikase. Our 2 Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Inhibikase Therapeutics ( (IKT)) has provided an announcement. Inhibikase Therapeutics entered an At the ...

Quite a few insiders have dramatically grown their holdings in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) over the past 12 months. An insider's optimism about the company's prospects is a positive ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a biopharmaceutical company, announced on Monday that its shareholders approved a significant amendment to its corporate charter to increase the number of ...